Cytogen Inc (217330) — Cash Flow-to-Debt Ratio
Cytogen Inc (217330) has a Cash Flow-to-Debt Ratio of -0.08x as of December 2025, meaning its operating cash flow of ₩-2.13 Billion could theoretically repay 0% of its total liabilities (₩26.25 Billion) in one year. See Cytogen Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cytogen Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Cytogen Inc across 12 annual periods. Also explore 217330 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cytogen Inc (2014–2025)
Year-by-year debt coverage analysis for Cytogen Inc. For market capitalisation and broader financial context, see 217330 market cap.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.26x | ₩-6.95 Billion | ₩26.25 Billion | ▲ +33.6% |
| 2024 | -0.40x | ₩-9.53 Billion | ₩23.89 Billion | ▼ -10.8% |
| 2023 | -0.36x | ₩-7.59 Billion | ₩21.09 Billion | ▼ -100.7% |
| 2022 | -0.18x | ₩-6.38 Billion | ₩35.56 Billion | ▼ -11.5% |
| 2021 | -0.16x | ₩-5.23 Billion | ₩32.52 Billion | ▲ +64.1% |
| 2020 | -0.45x | ₩-4.47 Billion | ₩9.97 Billion | ▲ +76.1% |
| 2019 | -1.88x | ₩-3.37 Billion | ₩1.80 Billion | ▲ +51.8% |
| 2018 | -3.89x | ₩-2.77 Billion | ₩711.51 Million | ▼ -69.3% |
| 2017 | -2.30x | ₩-2.18 Billion | ₩947.50 Million | ▼ -346.3% |
| 2016 | -0.52x | ₩-2.36 Billion | ₩4.59 Billion | ▲ +59.5% |
| 2015 | -1.27x | ₩-2.03 Billion | ₩1.60 Billion | ▼ -94.4% |
| 2014 | -0.65x | ₩-1.03 Billion | ₩1.57 Billion | — |